Myriad Genetics, Inc. MYGN recently announced updates to its agreement with Illumina Inc. ILMN. The company’s gold-standard Genomic Instability Score (“GIS”) to determine Homologous Recombination ...

Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.

Hangzhou Synrx Therapeutics Biomedical Technology Co. Ltd. recently presented the development and characterization of a novel PARG inhibitor, SYN-608, for the potential treatment of tumors ...

Eisbach Bio's innovative approach focuses on exploiting the unique genetic vulnerabilities present in solid tumors with deficiencies in certain DNA repair pathways. Eisbach's proprietary ALLOS ...

Science DNA breaks are toxic lesions for the cell. In order to repair these breaks, it is necessary, starting from the break ends, to find a homologous sequence within the vastness of the genome. In ...

Panelists discuss how the PROfound trial (NCT02987543) demonstrated the efficacy and safety of olaparib monotherapy in metastatic prostate cancer patients with homologous recombination repair gene ...

Screening for pancreatic cancer is recommended for individuals with the above risk factors around 50 years of age or 10 years ...

Covestor Ltd lifted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 23,050.0% during the third ...

Illumina currently has a market capitalization of $20.74 billion. The company’s earnings in 2024 are expected to surge nearly 343% compared to the industry’s 17.8% growth. In the trailing four ...

a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination ...

Pancreatic cancer, specifically pancreatic adenocarcinoma, remains one of the most aggressive and deadliest cancers worldwide ...